Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Serum soluble Fas levels in ovarian cancer
Autore:
Hefler, L; Mayerhofer, K; Nardi, A; Reinthaller, A; Kainz, C; Tempfer, C;
Indirizzi:
Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 tet & Gynecol, Houston, TX 77030 USA Univ Vienna, Sch Med, Dept Gynecol & Obstet, Vienna, Austria Univ Vienna Vienna Austria Med, Dept Gynecol & Obstet, Vienna, Austria Univ Vienna, Sch Med, Dept Med Comp Sci, Vienna, Austria Univ Vienna Vienna Austria Sch Med, Dept Med Comp Sci, Vienna, Austria
Titolo Testata:
OBSTETRICS AND GYNECOLOGY
fascicolo: 1, volume: 96, anno: 2000,
pagine: 65 - 69
SICI:
0029-7844(200007)96:1<65:SSFLIO>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
MEDIATED APOPTOSIS; DEATH FACTOR; MECHANISM; LIGAND; CD95; EXPRESSION; FAS/APO-1; DISEASE; SYSTEM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Hefler, L Baylor Coll Med, Dept Obstet & Gynecol, Smith Tower,6550 Fannin,Suite 901,Houston, TX 77030 USA Baylor Coll Med Smith Tower,6550 Fannin,Suite 901 Houston TX USA 77030
Citazione:
L. Hefler et al., "Serum soluble Fas levels in ovarian cancer", OBSTET GYN, 96(1), 2000, pp. 65-69

Abstract

Objective: To determine the value of serum soluble Fas levels as a prognostic marker for survival of women with ovarian cancer and as a discriminatorbetween benign and malignant adnexal masses. Methods: Serum soluble Fas levels were measured with an enzyme-linked immunosorbent assay in 52 women with ovarian cancer, 30 women with benign ovarian cysts, and 35 healthy women. Results: Median serum soluble Fas levels in women with ovarian cancer, women with benign ovarian cysts, and healthy women were 3.7 (range 1.6-14.5), 2.3 (range 1.3-4.1), and 1.5 ng/mL. (range 0.1-5.6), respectively (P <.001). A univariate logistic regression model showed a significant influence of serum soluble Fas and CA 125 levels on the odds of presenting with ovarian cancer versus benign cysts (P <.001 and P =.001, respectively). In a multivariable logistic regression model for soluble Fas and CA 125, both markers showed a statistically significant influence on the odds of presenting withovarian cancer versus benign cysts (P =.01 and P =.01, respectively). Increased pretreatment serum soluble Fas levels were associated with shortened disease-free and overall survival (P =.002 and P =.001, respectively). A multivariable Cox regression model identified serum soluble Fas levels as a significant prognostic factor for disease-free and overall survival, independent of tumor stage (P =.04 and P =.03, respectively). Conclusion: Soluble Fas levels might be useful as a discriminator between benign ovarian cysts and ovarian cancer, adding to the information obtainedwith the use of the established tumor marker CA 125. Pretreatment serum soluble Fas levels also might be an independent prognostic factor for disease-free and overall survival. (Obstet Gynecol 2000;96:65-9. (C) 2000 by The American College of Obstetricians and Gynecologists.).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 23:10:04